Coverage dated September 24, 2023 to September 27, 2023
FDA advisers vote against experimental ALS therapy pushed by patients
Headline from NBC Chicago, on the newest of 2 developments
In the last year, the FDA has approved two new drugs for ALS, after a nearly 20-year drought of new options. The approvals followed intense lobbying by advocacy groups
NBC Chicago's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
Developments in this update
2 dated developments, oldest first, newest marked. Each is named by one outlet's own headline; open its reports to see every outlet that covered it.
FDA skeptical of experimental ALS treatment pushed by patient advocates
Headline from The Columbian ·
Newest
FDA advisers vote against experimental ALS therapy pushed by patients
WASHINGTON (AP) — The Food and Drug Administration meets this week to consider approval of an experimental treatment for Lou Gehrig’s disease, the culmination of a yearslong lobbying effort by patient
In the last year, the FDA has approved two new drugs for ALS, after a nearly 20-year drought of new options. The approvals followed intense lobbying by advocacy groups
WASHINGTON — Federal health advisers voted overwhelmingly against an experimental treatment for Lou Gehrig’s disease at a Wednesday meeting prompted by years of patient efforts seeking access to the u
WASHINGTON (AP) — Federal health advisers voted overwhelmingly against an experimental treatment for Lou Gehrig’s disease at a Wednesday meeting prompted by years of patient efforts seeking access to the unproven therapy.
Federal health advisors voted 17-1 against an experimental treatment for Lou Gehrig's disease dubbed NurOwn, although the FDA is not bound by the vote.
Identical headlines usually mean shared wire copy. They are counted as separate articles but are not independent confirmation.
FDA advisers vote against experimental ALS therapy pushed by patients | Since Then
